T cell exhaustion pathway

The T cell exhaustion pathway encompasses a set of progressive and often irreversible changes in T cell function arising from chronic antigen exposure—such as in cancer or persistent viral infection. Exhausted T cells are defined by loss of effector function (cytokine production, cytolytic activity), reduced proliferative capacity, and upregulation of multiple inhibitory receptors (PD-1, CTLA-4, LAG-3, TIM-3, TIGIT, and others)[1][9][8]. These cells typically undergo distinctive metabolic and epigenetic changes, distinguishing them from effector or memory T cells[1][7][6]. T cell exhaustion limits effective anti-tumor and anti-viral immunity but also serves as a protective mechanism against immunopathology. Clinically, targeting the molecules and signaling nodes in this pathway—particularly with immune checkpoint inhibitors—has revolutionized cancer immunotherapy but also presents unique challenges such as variable efficacy and immune-related toxicity[2][5][8].

Other names

T cell dysfunction pathwayT cell exhaustion programTex pathwayexhaustion signaling pathway

Immune checkpoint blockade (e.g., PD-1/PD-L1 or CTLA-4 antibodies relieve inhibitory signals and restore T cell effector functions); Combination therapies targeting multiple checkpoints for synergistic reversal of exhaustion